This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT00477425
First received: May 21, 2007
Last updated: May 11, 2017
Last verified: May 2017
May 21, 2007
May 11, 2017
June 2007
June 2007   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00477425 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
Carcinoma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
June 2007
June 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Signed Informed Consent Form
  • Enrollment in one of a list of certain randomized, controlled bevacizumab trials

Exclusion Criteria:

  • Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)
  • Congenital long QT syndrome
  • Family history of long QT syndrome
  • Clinically significant bradycardia (defined as < 50 beats/minute)
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00477425
AVF4223g
Not Provided
Not Provided
Not Provided
Not Provided
Genentech, Inc.
Not Provided
Study Director: Jane Huang, M.D. Genentech, Inc.
Genentech, Inc.
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP